	

Teleconference Memorandum: Clinical Questions - Provenge, April 4, 2007


 
DEPARTMENT OF HEALTH AND HUMAN SERVICES     


TELECONFERENCE MEMORANDUM                                                        
                             Public Health Service
                                                                                 
                                            Food and Drug Administration
                                                                                 
                                            Center for Biologics Evaluation and 
Research
 

Date\Time:     April 4, 2007  

CBER Representatives:  Peter Bross

Sponsor’s Representative:  Helen Kim

STN :  125197/0

Subject:  Clinical Questions

Discussion:
  Please confirm whether the revised D9902B (SPA) protocol contained in 
  amendment 198 (serial number 198) was the most recent protocol (submission 
  date 11-OCT-2005). Please e-mail an electronic copy of the most recent 
  protocol to us including the SAP.

  DNDN Response:  Yes. 

  Please confirm whether the revised IDMC charter contained in amendment 200 
  (serial number 200) was the most recent one (submission date 11-OCT-2005). 
  Please send an electronic copy of the most recent IDMC charter to us.

  DNDN Response:  Yes. 

  Please update the D9902B enrollment status (blinded information of course) as 
  soon as possible: Number of subjects enrolled 

    DNDN Response:  As of April 1, 2007, a total of 403 subject have been 
    randomized.

    Percentage of African-American subjects enrolled 

    DNDN Response:  As of April 1, 2007, 4.1% of African American subjects have 
    enrolled.

     Updated death events after last annual report (26-MAR-07).

    DNDN Response:  As of April 1, 2007, there are a total 80 death events.  
    This represents 22% (80/360) of the targeted number of death events.


  Please also send an electronic copy of the most recent annual report since the 
  file in EDR is not accessible at this time.

  DNDN Response:  Per this afternoon's teleconference, please let us know if you 
  will still require an electronic version of the most recent BB-IND 6933 Annual 
  Report. 

  In your briefing document (p56) you stated that "Balance between treatment 
  arms for baseline prognostic factors was assessed using an independently 
  validated model (Halabi, 2003)..... Results of the analysis demonstrate that 
  the treatment arms were well-balanced. The median of the estimated survival 
  times for the patients in the sipuleucel-T and the placebo arms were highly 
  comparable, at 20.1 and 19.9 months, respectively.  Is there somewhere in the 
  BLA an analysis of the estimated survivals in trials 9901 and 9902A by the 
  Halabi model?  If not could you please ask your statistician to do this 
  analysis for the two arms separately and for the whole population of 9902A and 
  share the results with us?  We would like to try to understand why the 
  survivals are so different between 9901 and 9902A.

  DNDN Response: 

  Please note that the additional analyses contained in our response are based 
  upon data included in the initial BLA submission (submitted 21 August 2006).  
  Specifically:

  For Survival Data:  refer to BLA ITEM 8, Section 5.3.5.1, Study CSR-D9901, 
  Post-Text Listing 16.2.6.18, page 2390 of 5814.
  For the Immune Response Data:  refer to BLA ITEM 8, Section 5.3.5.1, Study 
  CSR-D9901, Post-Text Listing 16.2.6.20, page 2445 of 5814.

 